Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo Ford, Janet Dunn, Andrea Marshall et al.|The Lancet Oncology|2013Cited by 604
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Dónal Landers, Danielle Carroll et al.|Nature Medicine|2021Cited by 115
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinomaNatalie Cook, David A. Tuveson|The Journal of Experimental Medicine|2012Cited by 95
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statementSarah P. Blagden, A. Yiangou, Lucinda Billingham et al.|British Journal of Cancer|2020Cited by 44
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cell Reports Medicine|2025Cited by 12